-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
After the occurrence of TIA or non-myocardial infarction ischemic stroke, it is recommended to use antiplatelet drugs for life
Despite treatment, the residual risk of recurrent ischemic events is still very high, ≈5% per year
For the currently recommended antiplatelet regimens, on average, the reduction in ischemic events is greater than the increase in major bleeding
The prognostic model can be used to stratify the trial population and explore the impact of changes in absolute risk on the benefits and risks of treatment
In this way, Nina A.
According to the individual's bleeding risk, study the balance between the benefits and risks of long-term antiplatelet therapy
According to the risk of major bleeding predicted by the S2TOP-BLEED score, patients were stratified into five levels
37877 patients were included in the analysis
In all quintiles, the relative reduction in ischemic events (from 0.
Relatively reducing ischemic events (from 0.
The important significance of this study lies in the discovery that in patients with transient ischemic attack or ischemic stroke included in clinical trials of antiplatelet therapy, the risk of recurrence of ischemic events and major hemorrhage increases simultaneously
In patients with transient ischemic attack or ischemic stroke included in clinical trials of antiplatelet therapy, the risk of recurrence of ischemic events and major hemorrhage increased simultaneously
Original source:
Leave a message here
